Belite Bio (BLTE) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed Belite Bio (BLTE) over the past year, gaining 404.7% versus a gain of 95.4%. Spyre Therapeutics is the larger company by market cap ($7.37 billion vs $6.14 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLTE | SYRE |
|---|---|---|
| Share price | $152.52 | $79.90 |
| Market cap | $6.14B | $7.37B |
| 1-day change | -2.28% | -1.18% |
| YTD return | -4.65% | +146.79% |
| 1-year return | +95.39% | +404.68% |
| 5-year return | — | -60.46% |
| Forward P/E | 67.49 | — |
| EPS (TTM) | $-2.74 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-77.61M | $-155.20M |
| 52-week high | $200.00 | $110.18 |
| 52-week low | $77.13 | $17.65 |
| Distance from 52-week high | -23.74% | -27.48% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +50.07% | +50.45% |
| Average volume | 178.90K | 1.20M |
| Shares outstanding | 40.27M | 92.29M |
| Employees | 41 | 125 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed BLTE by 309.3 percentage points over the past year.
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 125 employees
BLTE vs SYRE FAQ
Which is bigger, Belite Bio or Spyre Therapeutics?
Spyre Therapeutics (SYRE) is larger, with a market capitalization of $7.37B compared with $6.14B for Belite Bio (BLTE).
Which stock has performed better over the past year, BLTE or SYRE?
SYRE returned +404.68% over the past 12 months, compared with +95.39% for BLTE (price return, excluding dividends). Past performance does not predict future results.
Are Belite Bio and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.